This press release contains certain forward-looking statements about the potential of prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical compound, there are substantial risks and uncertainties in the process of development, regulatory review, and commercialization. There is no guarantee that the compound will receive regulatory approvals, that the regulatory approvals will be for the indication(s) anticipated by the companies, or that later studies and patient experience will be consistent with study findings to date. There is also no guarantee that the compound will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.
Plavix(R) and Iscover(R) are registered trademarks of sanofi-aventis.
P--LLY
1. Thygesen K, Alpert JA, White HD, et al. Universal Definition of Myocardial Infarction. Circulation 2007;116:2634-2653.
2. Effect of the Novel Thienopyridine Prasugrel Compared with Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the TRITON-TIMI 38 Trial: an Application of the Universal Definition of Myocardial Infaction. Cardiology. Circulation. June 2, 2009.
3. Thygesen K, Alpert JA, White HD, et al. Universal Definition of Myocardial Infarction. Circulation 2007;116;2634-2653.
4. Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. November 2007;357:2001-15.
5. British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008, http://www.ehnheart.org/content/ItemPubl... vel1=2157, Accessed April 24 2008.
6. American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. Dallas, TX. American Heart Association. (Pg. 14)
7. WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease. June 2004.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )
Tammy Hull of Eli Lilly and Company, +1-317-651-9116 (office), +1-317-614-5132 (cell); or Kim Wix of Daiichi Sankyo (U.S.A.), +1-973-944-2338 (office), +1-908-656-5447 (cell), or Shigemichi Kondo of Daiichi Sankyo (Tokyo), +81-3-6225-1126 (office); Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO
